NIKKEI 225
39,116.84 +78.68 (+0.20%) HANG SENG
18,150.36 -216.59 (-1.18%) CRUDE OIL
77.65 -0.09 (-0.12%) GOLD FUTURES
2,316.40 -10.60 (-0.46%) DOW
38,868.04 +69.05 (+0.18%) Bitcoin GBP
53,365.61 -1,251.42 (-2.29%)
BCTX Jul 2024 5.000 put
| Previous close | 2.2500 |
| Open | 2.2500 |
| Bid | 1.7500 |
| Ask | 2.3000 |
| Strike | 5.00 |
| Expiry date | 2024-07-19 |
| Day's range | 2.2500 - 2.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireBriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patientsTherapy well-tolerated with no Bria-IMT™ related discontinuationsClinical data highlight significant potential of Bria-IMT™ in advanced metastatic breast cancerSuperiority of selected Phase 3 regimen and formulation confirmedOral presentation by Mayo Clinic Profe
GlobeNewswireBriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor ti
- GlobeNewswire
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASD
